Literature DB >> 18819095

Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension.

Eduard J van Beers1, Erfan Nur, Cornelia M Schaefer-Prokop, Melvin R Mac Gillavry, Joost W J van Esser, Dees P M Brandjes, Maria C Kappers-Klunne, Ashley J Duits, Frits A J Muskiet, John-John B Schnog, Bart J Biemond.   

Abstract

Pulmonary hypertension (PHT) occurs in approximately 30% of adults with sickle cell disease (SCD) and is an independent risk factor for early death. In this study, we aimed to determine the value of general laboratory testing, plain chest radiography, electrocardiography (ECG), high-resolution computer tomography (HRCT) of the thorax, pulmonary function testing, and plasma N-terminal brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP) in patients with SCD-related PHT. A cohort of 85 ambulatory sickle cell patients were prospectively screened for PHT with echocardiography (defined as a tricuspid regurgitation flow velocity of > or =2.5 m/sec). All patients were systematically evaluated by the aforementioned diagnostic tests comparing patients with and without PHT. The prevalence of PHT was 41% in HbSS/HbSbeta(0)-thalassemia patients and 13% in HbSC/HbSbeta(+)-thalassemia patients. No statistically significant differences were detected in ECG, chest radiography, HRCT, and pulmonary function testing between patients with and without PHT. The degree of anemia and renal dysfunction, but not the presence of PHT, were the most important determinants of plasma (NT-pro)BNP levels. The performed imaging and functional studies do not seem to be of value in identifying etiological conditions (such as airflow obstruction or parenchymal lung disease) nor do they offer clues to the presence of mild PHT in SCD. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18819095     DOI: 10.1002/ajh.21272

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors:  A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

Review 2.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

3.  Circulating fibrocytes as biomarkers of impaired lung function in adults with sickle cell disease.

Authors:  Borna Mehrad; Marie D Burdick; Nancy J Wandersee; Kaushik S Shahir; Liyun Zhang; Pippa M Simpson; Robert M Strieter; Joshua J Field
Journal:  Blood Adv       Date:  2017-11-06

4.  Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia.

Authors:  Caterina P Minniti; Jonathan Wilson; Laurel Mendelsohn; Greg C Rigdon; Jonathan W Stocker; Alan T Remaley; Gregory J Kato
Journal:  Br J Haematol       Date:  2011-06-08       Impact factor: 6.998

Review 5.  Intravascular hemolysis and the pathophysiology of sickle cell disease.

Authors:  Gregory J Kato; Martin H Steinberg; Mark T Gladwin
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.